CVS Health (CVS)
(Delayed Data from NYSE)
$59.32 USD
-0.71 (-1.18%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $59.30 -0.02 (-0.03%) 7:58 PM ET
4-Sell of 5 4
A Value A Growth B Momentum A VGM
Price, Consensus and EPS Surprise
CVS 59.32 -0.71(-1.18%)
Will CVS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CVS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CVS
CVS Health (CVS) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates
CVS Health (CVS) Stock Moves -0.5%: What You Should Know
CVS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Herbalife Ltd (HLF) Tops Q2 Earnings Estimates
Analysts Estimate CVS Health (CVS) to Report a Decline in Earnings: What to Look Out for
CVS Health (CVS) Stock Pre-Q2 Earnings: To Buy or Not to Buy?
Other News for CVS
Wall Street Breakfast: The Week Ahead
Ariel Investments Ariel Global Fund Q2 2024 Commentary
CVS stores in some cities run out of COVID tests as cases spike: Bloomberg
Ariel Investments Global Concentrated Q2 2024 Commentary
Ariel Investments Global Q2 2024 Commentary